Skip to main content
Patrick Moriarty, MD, Internal Medicine, Kansas City, KS

Patrick M Moriarty MD

Internal Medicine•Kansas City, KS

Adult Clinical & Laboratory Immunology

Physician

Join to View Full Profile

  • 3901 Rainbow BlvdMail Stop 3008Kansas City, KS 66160

  • Phone+1 913-588-6057

  • Fax+1 913-588-4074

Dr. Moriarty is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.
See Dr. Moriarty's Full ProfileAlready have an account?

Summary

  • Dr. Patrick Moriarty is a Professor of Medicine at the The University of Kansas Hospital. He received his medical degree from Sapienza University of Rome and has been in practice 26 years. He is Director of Clinical Pharmacology and the Atherosclerosis & Lipid-apheresis Center.
    is a fellow of the American College of Physicians, the American College of Cardiology, the European Society of Cardiology, National Lipid Association, and he was the 2014-2015 president of the International Society for Apheresis. He serves as a manuscript reviewer for multiple scientific journals and is the associate editor for the Journal of Clinical Apheresis and Clinical Lipidology.
    He has published over 100 peer reviewed articles/chapters. His research activities include such topics as atherosclerosis, familial hypercholesterolemia, Lp(a), Lipoprotein-Apheresis, vascular Inflammation, dementia and hemorheology. He has participated in numerous clinical trials related to dyslipidemia, Lp(a), obesity, hypertension, dementia, and diabetes. Moreover, Dr. Moriarty is a member of the scientific advisory board for the FH Foundation. His clinical activities involve the treatment and diagnosis of atherosclerosis and cardiovascular disease. The University of Kansas Lipoprotein-Apheresis Center is the largest in North America for the treatment of Familial Hypercholesterolemia and elevated Lp(a).

Education & Training

  • University of Kansas School of Medicine
    University of Kansas School of MedicineResidency, Internal Medicine, 1991 - 1994
  • Sapienza University of Rome
    Sapienza University of RomeClass of 1991
  • St. Michael's College
    St. Michael's CollegeBA

Certifications & Licensure

  • MO State Medical License
    MO State Medical License 2021 - 2027
  • KS State Medical License
    KS State Medical License 1994 - 2026
  • Internal Medicine
    National Board of Physicians and Surgeons Internal Medicine

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013, 2015-2017
  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013, 2015-2017
  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2013, 2015-2017

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Sever...  
    Raul D Santos, Samuel S Gidding, Robert A Hegele, Marina A Cuchel, Philip J Barter, Gerald F Watts, Seth J Baum, Alberico L Catapano, M John Chapman, Joep C Defesche, ..., Lancet Diabetes-Endocrinol, 1/1/2016
  • JCL Roundtable: PCSK9 Inhibitors in Clinical Practice  
    Brown WV, Moriarty PM, McKenney JM, Journal of Clinical Lipidology, 1/1/2016
  • JCL Roundtable: Should We Treat Elevations in Lp(a)?  
    Brown WV, Moriarty PM, Remaley AT, Tsimikas S, Journal of Clinical Lipidology, 1/1/2016

Books/Book Chapters

  • Clinical Lipidology: A Companion to Braunwald's Heart Disease 
    Chapter: Special Patient Populations: Familial Hypercholesterolemia and Other Severe Hypercholesterolemias 
    Page 440.0 - 453.0Moriarty PM, Santos RDSaunders/ElsevierEdition 2nd,2015
  • Cardiology Clinics: Lipidology 
    Chapter: Lipoprotein Apheresis 
    Page 197.0 - 208.0Moriarty PM, Hemphill Linda2015
  • Clinical Challenges in Lipid Disorders 
    Chapter: What is familial hypercholesterolemia and how should it be treated? 
    Moriarty PM, Backes J, Gibson CAClinical Publishing, Oxford

Abstracts/Posters

  • Impact Of Lipoprotein Apheresis on Serum Myeloperoxidase Levels in Patients with Familial Hypercholesterolemia
    Sehar N, Moriarty, PM, European Atherosclerosis Society, Glasgow, Scotland, 1/1/2015
  • Long Term Follow up of Bi-Weekly Lipoprotein Apheresis in A patient with Elevated Lipoprotein-(a) Shows Regression in Carotid Intima-Media Thickness
    Abeer Anabtawi, Priyanka Patel, Lisa Deuschele, Patrick Moriarty, National Lipid Association, Chicago, Illinois, 1/1/2015
  • Resolution of recurrent postoperative pericarditis after lipid apheresis: a case report
    Moriarty PM, Heckerson N, Journal of Clinical Lipidology, 1/1/2012

Lectures

  • Diagnosis and treatment of abnormal cholesterolemia in the diabetic patient including the metabolic syndrome patient 
    KU Med - 1/1/2005
  • Diabetic Lipid Management: How low should we go? 
    Kansas City, MO - 1/1/2005
  • Atherosclerosis and its association with hemorheology 
    St. Luke’s Hospital, Kansas City, MO - 1/1/2005

Other

Press Mentions

  • Fundraiser Planned for Child Who Suffered Strokes
    Fundraiser Planned for Child Who Suffered StrokesJuly 25th, 2015

Professional Memberships

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence:

Dr. Patrick Moriarty, Dr. Patrick Moriarty, MD, Dr. P Moriarty, Dr. Patrick M Moriarty